Dr Reddys Laboratories, an integrated global pharmaceutical company, announced today that it has entered into an agreement with Hetero, under which Dr. Reddy's has been licensed to distribute and market Sofosbuvir 400 mg tablets, indicated in the treatment of chronic Hepatitis C, under the brand name Resof, in India.

Dr Reddy's co-chairman & CEO, G V Prasad, commented, ''the launch of Resof is in line with Dr Reddy's philosophy of ''Innovative medicine at an affordable price'' and will provide significant relief to patients, resulting in potential cure and a high barrier to resistance at an affordable price for those living with Hepatitis C.

Shares of the company gained Rs 25.05, or 0.73%, to settle at Rs 3,454. The total volume of shares traded was 8,420 at the BSE (Monday).